Recurrent of Ovarian Cancer in BRCAwt Patients Without Maintenance Therapy: Real-World Evidence

Melinda Louie-Gao, Ebru Aydin, Premal H. Thaker

TIESARO A GSK Company, Wallingford, MA, USA; "Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO, USA

Objectives

• To assess the role of platinum eligibility loss for BRCAwt patients who did not receive maintenance therapy after platinum-based treatment in a real-world setting

METHODS

• This retrospective study included patients with OC from January 2011 to October 2015 using data from Flatiron, a longitudinal, demographically and geographically diverse database derived from records of >265 cancer clinics and >2 million US patients with cancer

RESULTS

• We identified 1033 patients diagnosed with OC of these, 147 BRCAwt patients met the inclusion criteria (see Table 1)

Table 2. Patient Demographics and Baseline Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>0–14</td>
<td>0.05</td>
</tr>
<tr>
<td></td>
<td>15–64</td>
<td>0.95</td>
</tr>
<tr>
<td></td>
<td>&gt;65</td>
<td>0.95</td>
</tr>
<tr>
<td>Race</td>
<td>White</td>
<td>0.75</td>
</tr>
<tr>
<td></td>
<td>Black</td>
<td>0.75</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>0.75</td>
</tr>
<tr>
<td>Type of therapy</td>
<td>Chemotherapy</td>
<td>0.75</td>
</tr>
<tr>
<td>Excluded patients</td>
<td>Number</td>
<td>0.75</td>
</tr>
<tr>
<td>Patients who had no maintenance after the current platinum-based CT</td>
<td>56%</td>
<td>0.75</td>
</tr>
</tbody>
</table>

CONCLUSIONS

• Our real-world data analysis shows that 56% of BRCAwt patients who received platinum-based CT without maintenance therapy had recurrent OC within 6 months after their last platinum-based CT, classifying them as platinum resistant:

- The use of maintenance treatment options, such as niraparib, has been shown to significantly prolong PFS after platinum-based CT and may be beneficial in extending the platinum-free interval, enabling patients to remain eligible for further platinum therapy

REFERENCES


ACKNOWLEDGMENTS

Writing and editorial support, funded by TESARO A GSK Company (Waltham, MA, USA) and coordinated by Heather O’Connell (Biostatistics, PhD), at TESARO were provided by Eric Scocchera (PhD), and Frederique H. Evans, MD, of Amgen-Chugai Healthcare Communications (Waltham, MA, USA) and the author of this poster.

Presented at the American Society of Clinical Oncology (ASCO) Annual Congress | May 31–June 4, 2019 | Chicago, IL

Figure 1. Study Design

Patients who received platinum-based CT

- Recurrence
- Maintenance
- No Maintenance

Estimate Probability of PD=6 Months After Lx

Fifth Line

Fourth Line

Third Line

Second Line

First Line

BRCAwt Patients Without Maintenance Therapy

BRCAwt Patients With Maintenance Therapy

BRCAwt Patients With No Cancer

Figure 2. Distribution of the Last Line of Platinum-Based CT (N=147)

Figure 3. Time to Next Treatment in BRCAwt Patients